Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
On May 4, 2011, the following individuals purchased Ordinary shares through dividend reinvestment within an Individual Savings Account (ISA) at a price of £13.15 per share:
- Mr A P Witty: 18 shares
- Mr S M Bicknell: 71 shares
- Mr E J Gray: 9 shares
- Mr D S Redfern: 9 shares
- Mrs V A Whyte: 16 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £13.15 per Ordinary share on May 4, 2011.
- Confirm the total number of shares acquired by directors via dividend reinvestment.
- Check subsequent filings for broader financial performance data not included in this specific transaction report.